Hence, we analyzed the expression of Cyclin D1, CDK2 and CDK4 in rigosertib-treated HNSCC cells and found that rigosertib significantly reduced the expression of these molecules in a dose-dependent manner. The gene discussed is CCND1; the disease is head and neck squamous cell carcinoma.